EpiVax is an American biotechnology company based in Rhode Island.[1] The company was founded in 1998 by Anne Searls De Groot, who serves as its CEO and CSO.[2] EpiVax holds the exclusive license to the EpiMatrix vaccine design technology.[3][2] In 2020 it developed a COVID-19 vaccine, EPV-CoV19, in partnership with the University of Georgia and Immunomic Therapeutics.[4][5][6]

References

  1. ↑ Graves, Helen (October 1, 2009). "Annie De Groot proves the power of one person". Boston Herald. Retrieved July 30, 2021.
  2. 1 2 "URI professor, vaccine pioneer honored by University of Chicago". URI News. University of Rhode Island. June 11, 2018. Retrieved July 30, 2021.
  3. ↑ MacMillan, John (June 15, 2020). "Dr. Annie De Groot '78: Designing a Vaccine". Grécourt Gate. Smith College. Retrieved July 30, 2021.
  4. ↑ Berkowitz, Bram (September 1, 2020). "Ocean State Update: The biggest Rhode Island tech and startup news From August". Rhode Island Innovation. Retrieved July 30, 2021.
  5. ↑ "7 Major Coronavirus Developments — RI's EpiVax to Raise $1.75M for Clinical Trial for Vaccine". GoLocalProv. April 8, 2020. Retrieved July 30, 2021.
  6. ↑ Tognini, Giacomo (April 1, 2020). "Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic". Forbes. Retrieved July 30, 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.